Sanara MedTech Inc. (SMTI)
USD 27.02
(-1.92%)
USD 27.02
(-1.92%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 6.64 Million USD | 181.63% |
| 2022 | -8.13 Million USD | 55.34% |
| 2021 | -18.22 Million USD | -70156.88% |
| 2020 | 26.01 Thousand USD | 100.58% |
| 2019 | -4.51 Million USD | -687.52% |
| 2018 | 768.15 Thousand USD | 4.25% |
| 2017 | 736.81 Thousand USD | -6.09% |
| 2016 | 784.62 Thousand USD | -52.18% |
| 2015 | 1.64 Million USD | 51.56% |
| 2014 | 1.08 Million USD | -29.72% |
| 2013 | 1.54 Million USD | -35.09% |
| 2012 | 2.37 Million USD | 73.96% |
| 2011 | 1.36 Million USD | -46.08% |
| 2010 | 2.53 Million USD | 84.68% |
| 2009 | 1.37 Million USD | -9.09% |
| 2008 | 1.5 Million USD | -0.02% |
| 2007 | 1.5 Million USD | 44.27% |
| 2006 | 1.04 Million USD | 24011.35% |
| 2005 | 4333.00 USD | 77.36% |
| 2004 | 2443.00 USD | 0.0% |
| 2001 | 2.09 Million USD | 7486.81% |
| 2000 | -28.41 Thousand USD | -102.7% |
| 1999 | 1.05 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 8.87 Million USD | 33.51% |
| 2024 Q2 | 10.12 Million USD | 14.15% |
| 2023 Q2 | -4 Million USD | 22.55% |
| 2023 FY | 6.64 Million USD | 181.63% |
| 2023 Q4 | 6.64 Million USD | 18.17% |
| 2023 Q3 | 5.62 Million USD | 240.32% |
| 2023 Q1 | -5.17 Million USD | 36.44% |
| 2022 FY | -8.13 Million USD | 55.34% |
| 2022 Q1 | -15.77 Million USD | 13.45% |
| 2022 Q2 | -12.37 Million USD | 21.59% |
| 2022 Q3 | -9.41 Million USD | 23.86% |
| 2022 Q4 | -8.13 Million USD | 13.58% |
| 2021 FY | -18.22 Million USD | -70156.88% |
| 2021 Q1 | -26.87 Million USD | -103406.05% |
| 2021 Q2 | -23.96 Million USD | 10.82% |
| 2021 Q4 | -18.22 Million USD | 16.73% |
| 2021 Q3 | -21.88 Million USD | 8.68% |
| 2020 FY | 26.01 Thousand USD | 100.58% |
| 2020 Q1 | -3.45 Million USD | 23.51% |
| 2020 Q2 | -2.18 Million USD | 36.83% |
| 2020 Q3 | -1.02 Million USD | 52.97% |
| 2020 Q4 | 26.01 Thousand USD | 102.54% |
| 2019 Q4 | -4.51 Million USD | -213.86% |
| 2019 Q1 | 1.48 Million USD | 93.37% |
| 2019 Q3 | 3.96 Million USD | 73.43% |
| 2019 Q2 | 2.28 Million USD | 53.87% |
| 2019 FY | -4.51 Million USD | -687.52% |
| 2018 Q1 | -261.44 Thousand USD | -135.48% |
| 2018 Q3 | 853.5 Thousand USD | 285.73% |
| 2018 Q4 | 768.15 Thousand USD | -10.0% |
| 2018 FY | 768.15 Thousand USD | 4.25% |
| 2018 Q2 | -459.52 Thousand USD | -75.76% |
| 2017 Q2 | 968.18 Thousand USD | -4.42% |
| 2017 Q3 | 1.27 Million USD | 31.43% |
| 2017 FY | 736.81 Thousand USD | -6.09% |
| 2017 Q1 | 1.01 Million USD | 29.1% |
| 2017 Q4 | 736.81 Thousand USD | -42.1% |
| 2016 Q1 | 1.47 Million USD | -9.94% |
| 2016 FY | 784.62 Thousand USD | -52.18% |
| 2016 Q2 | 1.47 Million USD | -0.25% |
| 2016 Q4 | 784.62 Thousand USD | -34.83% |
| 2016 Q3 | 1.2 Million USD | -18.33% |
| 2015 Q4 | 1.64 Million USD | -2.2% |
| 2015 Q2 | 1.53 Million USD | 21.21% |
| 2015 Q1 | 1.26 Million USD | 16.61% |
| 2015 FY | 1.64 Million USD | 51.56% |
| 2015 Q3 | 1.67 Million USD | 9.64% |
| 2014 FY | 1.08 Million USD | -29.72% |
| 2014 Q2 | 452.16 Thousand USD | 108.24% |
| 2014 Q1 | 217.13 Thousand USD | -85.9% |
| 2014 Q4 | 1.08 Million USD | 45.7% |
| 2014 Q3 | 743.04 Thousand USD | 64.33% |
| 2013 FY | 1.54 Million USD | -35.09% |
| 2013 Q3 | 2.44 Million USD | 5.74% |
| 2013 Q4 | 1.54 Million USD | -37.02% |
| 2013 Q1 | 2.01 Million USD | -15.09% |
| 2013 Q2 | 2.31 Million USD | 14.79% |
| 2012 FY | 2.37 Million USD | 73.96% |
| 2012 Q2 | 2.01 Million USD | -17.41% |
| 2012 Q3 | 2.41 Million USD | 20.31% |
| 2012 Q4 | 2.37 Million USD | -1.9% |
| 2012 Q1 | 2.43 Million USD | 78.46% |
| 2011 Q3 | 1.54 Million USD | -30.44% |
| 2011 Q4 | 1.36 Million USD | -11.66% |
| 2011 FY | 1.36 Million USD | -46.08% |
| 2011 Q2 | 2.22 Million USD | 216.6% |
| 2011 Q1 | 701.23 Thousand USD | -72.28% |
| 2010 FY | 2.53 Million USD | 84.68% |
| 2010 Q3 | 2.97 Million USD | 9.82% |
| 2010 Q4 | 2.53 Million USD | -14.83% |
| 2010 Q1 | 2.45 Million USD | 79.48% |
| 2010 Q2 | 2.7 Million USD | 10.0% |
| 2009 FY | 1.37 Million USD | -9.09% |
| 2009 Q4 | 1.37 Million USD | 43.94% |
| 2009 Q3 | 951.78 Thousand USD | 54.07% |
| 2009 Q2 | 617.75 Thousand USD | 44.21% |
| 2009 Q1 | 428.36 Thousand USD | 37609.98% |
| 2008 Q1 | 518.05 Thousand USD | -65.63% |
| 2008 Q4 | -1142.00 USD | -100.13% |
| 2008 Q3 | 908.69 Thousand USD | -3.87% |
| 2008 Q2 | 945.23 Thousand USD | 82.46% |
| 2008 FY | 1.5 Million USD | -0.02% |
| 2007 Q2 | 1.35 Million USD | 15.73% |
| 2007 Q3 | 1.32 Million USD | -1.87% |
| 2007 FY | 1.5 Million USD | 44.27% |
| 2007 Q4 | 1.5 Million USD | 13.46% |
| 2007 Q1 | 1.16 Million USD | 11.97% |
| 2006 Q1 | 9460.00 USD | 118.32% |
| 2006 Q2 | -11.88 Thousand USD | -225.63% |
| 2006 Q4 | 1.04 Million USD | 34724.83% |
| 2006 Q3 | 3000.00 USD | 125.24% |
| 2006 FY | 1.04 Million USD | 24011.35% |
| 2005 Q3 | -1957.00 USD | -133.12% |
| 2005 Q2 | 5909.00 USD | -98.13% |
| 2005 Q4 | 4333.00 USD | 321.41% |
| 2005 FY | 4333.00 USD | 77.36% |
| 2005 Q1 | 316.12 Thousand USD | 12840.2% |
| 2004 Q2 | 522.87 Thousand USD | 8.13% |
| 2004 Q3 | 527.5 Thousand USD | 0.89% |
| 2004 FY | 2443.00 USD | 0.0% |
| 2004 Q4 | 2443.00 USD | -99.54% |
| 2004 Q1 | 483.54 Thousand USD | 0.0% |
| 2002 Q1 | 6741.00 USD | -99.68% |
| 2001 Q2 | 54.09 Thousand USD | -96.94% |
| 2001 Q3 | 2.19 Million USD | 3956.79% |
| 2001 Q4 | 2.09 Million USD | -4.35% |
| 2001 Q1 | 1.76 Million USD | 6317.69% |
| 2001 FY | 2.09 Million USD | 7486.81% |
| 2000 Q4 | -28.41 Thousand USD | -101.82% |
| 2000 Q1 | 1.18 Million USD | 0.0% |
| 2000 Q3 | 1.55 Million USD | 9.34% |
| 2000 FY | -28.41 Thousand USD | -102.7% |
| 2000 Q2 | 1.42 Million USD | 19.9% |
| 1999 FY | 1.05 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 2.58 Million USD | -157.454% |
| AngioDynamics, Inc. | -70.14 Million USD | 109.473% |
| AtriCure, Inc. | -9.81 Million USD | 167.695% |
| Avinger, Inc. | 10.12 Million USD | 34.339% |
| Azenta, Inc. | -618.47 Million USD | 101.074% |
| BioLife Solutions, Inc. | 7.25 Million USD | 8.384% |
| The Cooper Companies, Inc. | 2.44 Billion USD | 99.729% |
| Daxor Corporation | 755.65 Thousand USD | -779.351% |
| Ekso Bionics Holdings, Inc. | -1.47 Million USD | 552.034% |
| Femasys Inc. | -15.01 Million USD | 144.254% |
| GlucoTrack, Inc. | -4.29 Million USD | 254.676% |
| Harvard Bioscience, Inc. | 38.49 Million USD | 82.736% |
| Hologic, Inc. | 374.4 Million USD | 98.225% |
| ICU Medical, Inc. | 1.45 Billion USD | 99.542% |
| Intuitive Surgical, Inc. | -2.66 Billion USD | 100.25% |
| KORU Medical Systems, Inc. | -7.03 Million USD | 194.426% |
| LeMaitre Vascular, Inc. | -5.17 Million USD | 228.429% |
| Innovative Eyewear, Inc. | -4.28 Million USD | 254.985% |
| Innovative Eyewear, Inc. | -4.28 Million USD | 254.985% |
| Masimo Corporation | 804 Million USD | 99.174% |
| Microbot Medical Inc. | -2.28 Million USD | 390.678% |
| Meihua International Medical Technologies Co., Ltd. | -9.59 Million USD | 169.248% |
| Merit Medical Systems, Inc. | 302.22 Million USD | 97.801% |
| Nephros, Inc. | -2.47 Million USD | 368.915% |
| NovoCure Limited | 355.42 Million USD | 98.13% |
| NEXGEL, Inc. | 98 Thousand USD | -6680.504% |
| NEXGEL, Inc. | 98 Thousand USD | -6680.504% |
| Singular Genomics Systems, Inc. | 59.05 Million USD | 88.748% |
| OraSure Technologies, Inc. | -276.9 Million USD | 102.4% |
| Pro-Dex, Inc. | 10.91 Million USD | 39.127% |
| Pulse Biosciences, Inc. | -35.22 Million USD | 118.866% |
| Predictive Oncology Inc. | -5.87 Million USD | 213.165% |
| Precision Optics Corporation, Inc. | 3.02 Million USD | -119.363% |
| QuidelOrtho Corporation | 2.49 Billion USD | 99.734% |
| Repligen Corporation | -39.51 Million USD | 116.814% |
| STAAR Surgical Company | -147.2 Million USD | 104.514% |
| Sharps Technology, Inc. | -3.01 Million USD | 320.548% |
| Utah Medical Products, Inc. | -92.52 Million USD | 107.182% |
| DENTSPLY SIRONA Inc. | 1.96 Billion USD | 99.662% |
| Jin Medical International Ltd. | -2.81 Million USD | 335.927% |